CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VIA Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VIA Pharmaceuticals Inc
750 Battery St Ste 330
Phone: (415) 283-2200p:415 283-2200 SAN FRANCISCO, CA  94111-1525  United States Ticker: VIAP VIAP
This company ceased filing statements with the SEC on 3/25/2011.
Business Summary
VIA Pharmaceuticals, Inc. (VIA) is a development-stage biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. The Company’s lead compound, VIA-2291, targets an unmet medical need of reducing atherosclerotic plaque inflammation, which is an underlying cause of atherosclerosis and its complications. Atherosclerosis is a cardiovascular disease that results from chronic inflammation and the build-up of plaque in arterial blood vessel walls. The Company’s clinical development strategy integrates several technologies to provide clinical proof-of-concept, as early as possible in the clinical development process. These technologies include the measurement of biomarkers, medical imaging of the coronary and carotid vessel walls to evaluate the plaque characteristics, and atherosclerotic plaque bioassays.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201012/31/2010YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Douglass B.Given 69 6/5/2007 6/5/2007
President, Chief Executive Officer, Director Lawrence K.Cohen 57 6/5/2007 6/5/2007
Principal Financial Officer, Vice President, Controller Karen S.Wright 56 4/30/2010 4/30/2010
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Corautus Genetics Inc.
Vascular Genetics Inc.
VEGF
VIA Pharma UK Limited
VIA Pharmaceuticals, Inc.
VIAP

General Information
Number of Employees: 6 (As of 12/31/2010)
Outstanding Shares: 20,560,446 (As of 12/31/2010)
Shareholders: 122
Stock Exchange: OTC
Federal Tax Id: 330687976
Fax Number: (302) 655-5049
Email Address: ir@genstar-rx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023